Mesenchymal stem cells: future source for reparative medicine.

Rinky Bhatia, Joshua M. Hare

Research output: Contribution to journalArticle

Abstract

Current treatments for ischemic cardiomyopathy are aimed toward minimizing the deleterious consequences of damaged myocardium. The possibility of treating heart failure by generating new myocardium and vascular structures has provided major impetus for recent stem cell research. Mesenchymal stem cells (MSCs), also referred to as marrow stromal cells, differentiate into a wide variety of lineages, including myocardial smooth muscle and possibly endothelial cells. The multilineage potential of MSCs, their ability to elude detection by the host's immune system, and their relative ease of expansion in culture make MSCs a very promising source of stem cells for transplantation. This paper reviews animal and human trials studying the role of MSCs in cardiomyogenesis and vasculogenesis in postinfarct myocardium, factors that stimulate MSC differentiation, routes of MSC delivery, and methods of detecting MSC engraftment.

Original languageEnglish (US)
JournalCongestive heart failure (Greenwich, Conn.)
Volume11
Issue number2
StatePublished - Mar 2005

Fingerprint

Mesenchymal Stromal Cells
Medicine
Myocardium
Stem Cell Research
Stem Cell Transplantation
Stromal Cells
Cardiomyopathies
Smooth Muscle
Blood Vessels
Cell Differentiation
Immune System
Endothelial Cells
Heart Failure
Bone Marrow

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mesenchymal stem cells : future source for reparative medicine. / Bhatia, Rinky; Hare, Joshua M.

In: Congestive heart failure (Greenwich, Conn.), Vol. 11, No. 2, 03.2005.

Research output: Contribution to journalArticle

@article{5a8d0f52465a4dc29bb98eee89a66984,
title = "Mesenchymal stem cells: future source for reparative medicine.",
abstract = "Current treatments for ischemic cardiomyopathy are aimed toward minimizing the deleterious consequences of damaged myocardium. The possibility of treating heart failure by generating new myocardium and vascular structures has provided major impetus for recent stem cell research. Mesenchymal stem cells (MSCs), also referred to as marrow stromal cells, differentiate into a wide variety of lineages, including myocardial smooth muscle and possibly endothelial cells. The multilineage potential of MSCs, their ability to elude detection by the host's immune system, and their relative ease of expansion in culture make MSCs a very promising source of stem cells for transplantation. This paper reviews animal and human trials studying the role of MSCs in cardiomyogenesis and vasculogenesis in postinfarct myocardium, factors that stimulate MSC differentiation, routes of MSC delivery, and methods of detecting MSC engraftment.",
author = "Rinky Bhatia and Hare, {Joshua M.}",
year = "2005",
month = "3",
language = "English (US)",
volume = "11",
journal = "Prevention and Management of Congestive Heart Failure",
issn = "1527-5299",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Mesenchymal stem cells

T2 - future source for reparative medicine.

AU - Bhatia, Rinky

AU - Hare, Joshua M.

PY - 2005/3

Y1 - 2005/3

N2 - Current treatments for ischemic cardiomyopathy are aimed toward minimizing the deleterious consequences of damaged myocardium. The possibility of treating heart failure by generating new myocardium and vascular structures has provided major impetus for recent stem cell research. Mesenchymal stem cells (MSCs), also referred to as marrow stromal cells, differentiate into a wide variety of lineages, including myocardial smooth muscle and possibly endothelial cells. The multilineage potential of MSCs, their ability to elude detection by the host's immune system, and their relative ease of expansion in culture make MSCs a very promising source of stem cells for transplantation. This paper reviews animal and human trials studying the role of MSCs in cardiomyogenesis and vasculogenesis in postinfarct myocardium, factors that stimulate MSC differentiation, routes of MSC delivery, and methods of detecting MSC engraftment.

AB - Current treatments for ischemic cardiomyopathy are aimed toward minimizing the deleterious consequences of damaged myocardium. The possibility of treating heart failure by generating new myocardium and vascular structures has provided major impetus for recent stem cell research. Mesenchymal stem cells (MSCs), also referred to as marrow stromal cells, differentiate into a wide variety of lineages, including myocardial smooth muscle and possibly endothelial cells. The multilineage potential of MSCs, their ability to elude detection by the host's immune system, and their relative ease of expansion in culture make MSCs a very promising source of stem cells for transplantation. This paper reviews animal and human trials studying the role of MSCs in cardiomyogenesis and vasculogenesis in postinfarct myocardium, factors that stimulate MSC differentiation, routes of MSC delivery, and methods of detecting MSC engraftment.

UR - http://www.scopus.com/inward/record.url?scp=23044509993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044509993&partnerID=8YFLogxK

M3 - Article

C2 - 15860974

AN - SCOPUS:23044509993

VL - 11

JO - Prevention and Management of Congestive Heart Failure

JF - Prevention and Management of Congestive Heart Failure

SN - 1527-5299

IS - 2

ER -